Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • vaxherra
    Junior Member
    • Jul 2016
    • 1

    #1

    Metagenomic survey of gut microbiota - depth, tradeoff and num. of samples to include

    Hi there community!

    I am a student currently enrolled in a Research Traineeship Program. My lab studies Systemic Lupus Erythematosus (SLE), and as a part of this research we are investigating microbiome in SLE patients and comparing to control groups.

    So far, we've done 16S rRNA amplicon sequencing of those patients. Some data were generated while I wasn't here (34 fecal samples, 15 controls, 19 SLE patients), and some are fairly recent (75 fecal samples, 25 controls, 50 SLE patients). Still not all samples have been sequenced, some failed PCR, and we'll be soon ordering mock communities in order to enhance our analyses, as some of the outcome results are pipeline-dependent (soft for OTU picking, filtering parameters etc.).

    Since 16S rRNA seems to be inefficient in exploring this immune disease, and "predictive metagenomics" (with PICRUSt software) is far too inaccurate, since the sequences that fail to map to reference (GreenGenes) are thrown out, we've decided to go with Shotgun Sequencing.

    Having read some papers (like: "How much metagenomic sequencing is enough to achieve a given goal?"), it is recommended to use at least 7Gbp (assuming x20 coverage to enumerate gene contents of prokaryotes with relative abundance of more than 1% in the human microbiota). Having 109 samples this is far too expensive. As a first step, I though about sticking to latest dataset, with 75 samples - i.e. reducing the number of samples to sequence. But this is too expensive (75 samples * 7GBp = 525).

    I don't have that much of an experience here, therefore I'd like to ask you, dear community, to help me out here. Direct me to some materials, or provide some suggestions. I don't want to remove patients from my dataset, as statistic power would decrease, but at the same time reducing depth could lead to "shallow" data. What are you thoughts?

    I have "paid" access to Illumina machines listed below:


    Best
    Robert.

Latest Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 08-06-2026, 07:41 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-03-2026, 10:13 AM
0 responses
38 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-31-2026, 02:55 AM
0 responses
43 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
26 views
0 reactions
Last Post SEQadmin2  
Working...